<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Stone, John H.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Early Results Indicate Rituximab Effective in the Treatment of IgG4-Related Disease</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-19</style></pages><abstract><style  face="normal" font="default" size="100%">Immunoglobulin G4-related disease (IgG4-RD) is a fibro-inflammatory disorder that was first described 10 years ago. IgG4-RD may affect multiple organs and resembles other diseases such as Sjögren's syndrome, lupus, sarcoidosis, lymphoma, and idiopathic membranous glomerulonephropathy. This article provides an overview of the results of a prospective open-label investigator-initiated trial of rituximab in the treatment of IgG4-related disease [NCT1584388].</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>